Progressive Supranuclear Palsy Market Size in the 7MM was ~USD 8.3 million in 2022 and is projected to grow during the forecast period (2023-2032), estimates DelveInsight | Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Transposon Therapeutics, O

DelveInsight's "Progressive Supranuclear Palsy Drugs Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the progressive supranuclear palsy historical and forecasted epidemiology as well as the market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Progressive Supranuclear Palsy Market Share @ Progressive Supranuclear Palsy Market Outlook- https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Progressive Supranuclear Palsy Market Report
• In March 2025, Ferrer Internacional S.A. organized a study to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
• In 2022, the total progressive supranuclear palsy prevalence cases were estimated to be approximately 80,706 cases in the 7MM. These cases are projected to increase during the forecast period.
• In the US, there were approximately 21,087 progressive supranuclear palsy prevalence cases in 2022. These cases are expected to increase by 2032.
• In 2022, among the 7MM, Japan accounted for the highest progressive supranuclear palsy prevalence cases, contributing nearly 29%, while Spain accounted for the least with nearly 7% of the total prevalent cases.
• Of the total progressive supranuclear palsy prevalence cases in the US, around 27% were diagnosed in 2022. The cases are expected to increase at a CAGR of 1.1%.
• Among the 7MM, the US accounted for the largest diagnosed prevalent progressive supranuclear palsy population contributing nearly 33% to the total diagnosed population in 2022. In contrast, Spain accounted for the least, with approximately 5% share of the total population in 2022.
• Among EU4 and the UK, Germany accounted for the highest diagnosed prevalence of progressive supranuclear palsy with approximately 1,646 cases, while with approximately 941 cases, Spain reported the least.
• According to estimates based on DelveInsight's epidemiology model, progressive supranuclear palsy affects more males than females. In EU4 and the UK, there were around 3,655 males and 2,536 females diagnosed with progressive supranuclear palsy in 2022, and the cases are expected to increase during the forecast period.
• According to the epidemiology model, in 2022, the phenotype-specific cases, progressive supranuclear palsy with Richardson's syndrome, progressive supranuclear palsy with Parkinsonism, and progressive supranuclear palsy with other phenotypes accounted for approximately 50%, 33%, and 17%, respectively, in EU4 and the UK.
• In Japan, among the comorbidities associated with progressive supranuclear palsy, nervous system disorders had the highest cases (approximately 5,077), while non-traumatic joint disorders had the least cases (approximately 4,457) in 2022.
• The leading Progressive Supranuclear Palsy Companies such as Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Transposon Therapeutics, Oncolys Biopharma, Ferrer Asceneuron, UCB Biopharma, Novartis, and others
• Promising Progressive Supranuclear Palsy Therapies such as BRAVYL (fasudil), AZP2006 (ezeprogind), TPN-101/OBP-601 (censavudine), ASN90, NIO752, UCB0107 (bepranemab), and others

Stay ahead in the Progressive Supranuclear Palsy Therapeutics Market with DelveInsight's Strategic Report @ Progressive Supranuclear Palsy Market Outlook- https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Progressive Supranuclear Palsy Epidemiology Segmentation in the 7MM
• Progressive Supranuclear Palsy Prevalent cases
• Progressive Supranuclear Palsy Diagnosed prevalent cases
• Progressive Supranuclear Palsy Gender-specific cases
• Progressive Supranuclear Palsy Phenotype-specific cases

Download the report to understand which factors are driving Progressive Supranuclear Palsy Epidemiology trends @ Progressive Supranuclear Palsy Prevalence- https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Emerging Progressive Supranuclear Palsy Drugs
• BRAVYL (fasudil): Woolsey Pharmaceutical/Asahi Kasei Pharma
BRAVYL is a small molecule, repurposed, oral version of fasudil, a potent inhibitor of Rho-kinases (ROCK) that are elevated in progressive supranuclear palsy and are involved in the accumulation of tau aggregates that lead to progressive supranuclear palsy. ROCK is an enzyme important in mediating vasoconstriction and vascular remodeling in the pathogenesis of pulmonary hypertension. ROCK induces vasoconstriction by phosphorylating the myosin-binding subunit of myosin light chain (MLC) phosphatase, thus decreasing MLC phosphatase activity and enhancing vascular smooth muscle contraction. ERIL, an IV formulation of fasudil, is approved in Japan for treating cerebral vasospasm and delayed cerebral ischemic symptoms after subarachnoid hemorrhage. Embark Healthcare launched Woolsey Pharmaceutical, its portfolio company, toward the end of 2019. BRAVYL (fasudil) is currently being tested in Phase IIa clinical studies for progressive supranuclear palsy - Richardson's syndrome and CBS.

• AZP2006 (ezeprogind): AlzProtect
AZP2006 (ezeprogind) is an orally available small molecule with a novel mechanism of action and effects. It involves the action of a neurotrophic factor, which combines reinforced neuroprotective efficacy and anti-neuroinflammation activity. AZP2006 blocks tau phosphorylation by stabilizing the prosaposin-progranulin complex. The stabilization prevents progranulin cleavage and increases progranulin secretion, further protecting the central neurons in progressive supranuclear palsy patients. Moreover, it also inhibits microglial activation and pro-inflammatory cytokine production. AZP2006 has exceptional therapeutic potential to treat the physiopathological causes of progressive supranuclear palsy and other related tauopathies such as Alzheimer's disease. The company has completed the Phase IIa study to treat progressive supranuclear palsy and showed positive and promising results.

Progressive Supranuclear Palsy Drugs Market Insights
Progressive supranuclear palsy is a rare neurodegenerative disorder resulting from damage to nerve cell clusters called nuclei (supranuclear) in the brain, deteriorating balance while walking, speech difficulties, trouble in swallowing, changes in mood and behavior, and cognitive impairment. Progressive supranuclear palsy is characterized pathologically by four-repeat (4R) Tau deposition in various cell types and anatomical regions. The mean onset age is 63 years, and the mean survival is 6-9 years. No specific laboratory tests or imaging approaches exist to diagnose progressive supranuclear palsy definitively.

To learn more about Progressive Supranuclear Palsy Treatment guidelines, visit @ Progressive Supranuclear Palsy Treatment Market Landscape- https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Progressive Supranuclear Palsy Market Outlook
Progressive supranuclear palsy, an atypical Parkinsonian condition, is characterized by a range of motor and behavioral syndromes associated with 4-repeat tau neuropathology. Early falls, supranuclear gaze palsy, axial and limb rigidity, and motor eyelid disorders are common disease symptoms. The typical age of disease onset is in the fifth to seventh decade of life. Several phenotypes of progressive supranuclear palsy have been defined over the past few years; PSP-RS, PSP-P, PSP-CBS, and PSP-PGF are a few common among them. Further, due to its complex presentation of phenotype and overlapping symptoms with neurodegenerative disorders, missed and delayed diagnosis is common and an obstacle in managing progressive supranuclear palsy. Similar symptoms in other neurological disorders complicate diagnosis and make differential diagnosis an imperative factor.

Scope of the Progressive Supranuclear Palsy Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Progressive Supranuclear Palsy Companies- Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Transposon Therapeutics, Oncolys Biopharma, Ferrer Asceneuron, UCB Biopharma, Novartis, and others
• Progressive Supranuclear Palsy Therapies- BRAVYL (fasudil), AZP2006 (ezeprogind), TPN-101/OBP-601 (censavudine), ASN90, NIO752, UCB0107 (bepranemab), and others
• Progressive Supranuclear Palsy Market Dynamics: Progressive Supranuclear Palsy Market Drivers and Barriers
• Progressive Supranuclear Palsy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Learn more about the FDA-approved drugs for Progressive Supranuclear Palsy @ Drugs for Progressive Supranuclear Palsy Treatment- https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Progressive Supranuclear Palsy Report Introduction
3. Progressive Supranuclear Palsy Market Overview at a Glance
4. Methodology of Progressive Supranuclear Palsy Epidemiology and Market
5. Progressive Supranuclear Palsy Executive Summary
6. Key Events
7. Progressive Supranuclear Palsy Disease Background and Overview
8. Progressive Supranuclear Palsy Patient Journey
9. Progressive Supranuclear Palsy Epidemiology and Patient Population
10. Emerging Progressive Supranuclear Palsy Drugs
11. Progressive Supranuclear Palsy Market Analysis
12. Key Opinion Leaders' Views
13. SWOT
14. Progressive Supranuclear Palsy Unmet Needs
15. Progressive Supranuclear Palsy Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimers
19. About DelveInsight

List of Top Selling Market Research Reports in 2025

Biopsy devices market- https://www.delveinsight.com/report-store/biopsy-devices-market
Diabetic wound market - https://www.delveinsight.com/report-store/diabetic-wounds-market
Joint reconstruction devices market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Heart failure market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive airway pressure device market - https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
Attention deficit hyperactivity disorder adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
Lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.